MENU
+Compare
BBP
ETF ticker: NYSE ARCA
AS OF
Jul 24, 04:08 PM (EDT)
Price
$63.22
Change
-$0.78 (-1.22%)
Net Assets
25.62M

BBP stock forecast, quote, news & analysis

The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index... Show more

Category: #Health
BBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for BBP with price predictions
Jul 23, 2025

BBP's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for BBP turned positive on July 09, 2025. Looking at past instances where BBP's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 02, 2025. You may want to consider a long position or call options on BBP as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BBP advanced for three days, in of 313 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 212 cases where BBP Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for BBP moved out of overbought territory on July 11, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 13 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

BBP broke above its upper Bollinger Band on July 09, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL), BioCryst Pharmaceuticals (NASDAQ:BCRX), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX).

Industry description

The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index. Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration ("FDA") for marketing.

Market Cap

The average market capitalization across the Virtus LifeSci Biotech Products ETF ETF is 13.09B. The market cap for tickers in the group ranges from 219.23M to 151.69B. AMGN holds the highest valuation in this group at 151.69B. The lowest valued company is YMAB at 219.23M.

High and low price notable news

The average weekly price growth across all stocks in the Virtus LifeSci Biotech Products ETF ETF was 1%. For the same ETF, the average monthly price growth was 7%, and the average quarterly price growth was 0%. IOVA experienced the highest price growth at 41%, while SRPT experienced the biggest fall at -41%.

Volume

The average weekly volume growth across all stocks in the Virtus LifeSci Biotech Products ETF ETF was 48%. For the same stocks of the ETF, the average monthly volume growth was 72% and the average quarterly volume growth was 102%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 62
P/E Growth Rating: 75
Price Growth Rating: 52
SMR Rating: 81
Profit Risk Rating: 79
Seasonality Score: -15 (-100 ... +100)
View a ticker or compare two or three
BBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
501 Madison Avenue, Suite 501New YorkNew York
Phone
(212) 593-4383
Web
N/A